Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial

Lessons from the RV144 Thai Phase III HIV-1 Vaccine Trial and the Search for Correlates of Protection

(2015) Jerome H. Kim et al.   Annual Review of Medicine

Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology

(2015) Amy W. Chung et al.   CELL

COMPASS identifies T-cell subsets correlated with clinical outcomes

(2015) Lin Lin et al.   NATURE BIOTECHNOLOGY

HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition

(2015) Heather A. Prentice et al.   Science Translational Medicine

HIV Vaccine Efficacy and Immune Correlates of Risk

(2014) Robert O'Connell et al.   CURRENT HIV RESEARCH

Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection

(2014) Susan Zolla-Pazner et al.   PLoS One

Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines

(2014) A. W. Chung et al.   Science Translational Medicine

Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination

(2014) N. L. Yates et al.   Science Translational Medicine

B-cell exhaustion in HIV infection

(2014) Susan Moir et al.   Current Opinion in HIV and AIDS

Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1

(2013) Marcella Sarzotti-Kelsoe et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies

(2013) A. deCamp et al.   JOURNAL OF VIROLOGY

Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine

(2013) Scott M. Hammer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial

(2013) Raphael Gottardo et al.   PLoS One

Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG

(2013) G. D. Tomaras et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120

(2012) Nicos Karasavvas et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials

(2012) D. C. Montefiori et al.   JOURNAL OF INFECTIOUS DISEASES

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144

(2012) Merlin L Robb et al.   LANCET INFECTIOUS DISEASES

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

(2012) Morgane Rolland et al.   NATURE

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

(2012) Barton F. Haynes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells

(2011) Christopher A. Todd et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study

(2011) Glenda E Gray et al.   LANCET INFECTIOUS DISEASES

Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand

(2011) Punnee Pitisuttithum et al.   PLoS One

Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate

(2010) Jeffrey R. Currier et al.   PLoS One

Duration of antigen receptor signaling determines T-cell tolerance or activation

(2010) S. D. Katzman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

(2009) Supachai Rerks-Ngarm et al.   NEW ENGLAND JOURNAL OF MEDICINE

Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia

(2008) G. D. Tomaras et al.   JOURNAL OF VIROLOGY

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

(2008) Susan P Buchbinder et al.   LANCET